As­traZeneca's ‘ra­diosen­si­tiz­er’ may en­hance ef­fi­ca­cy of ra­di­a­tion for dead­ly brain can­cer: #AACR24

Re­searchers are test­ing an ex­per­i­men­tal drug de­vel­oped by As­traZeneca with ra­di­a­tion to see if pair­ing the treat­ments will boost ra­di­a­tion’s ef­fi­ca­cy in glioblas­toma, a no­to­ri­ous­ly dif­fi­cult can­cer to treat.

The As­traZeneca treat­ment, dubbed AZD1390, in­hibits a DNA re­pair en­zyme called ATM. AZD1390 is meant to act as a “ra­diosen­si­tiz­er”; it aims to pre­vent DNA from re­pair­ing af­ter ra­di­a­tion dam­ages the DNA in can­cer cells. And pre­clin­i­cal da­ta have sug­gest­ed that tu­mor tis­sue ap­pears es­pe­cial­ly vul­ner­a­ble to AZD1390’s re­pair in­hi­bi­tion, ra­di­a­tion on­col­o­gist Jonathan Yang told End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER